SiBone (NASDAQ:SIBN) Given Average Recommendation of "Moderate Buy" by Analysts
Analysts have given SiBone (NASDAQ:SIBN) a "Moderate Buy" consensus rating, with an average 12-month price target of $24.67. Insider selling by CEO Laura Francis and other insiders has been noted, although institutional ownership remains high at 98.11%. The company recently exceeded EPS estimates and saw its revenue align with projections.
Si-Bone CFO Maheshwari sells $42,707 in stock
Anshul Maheshwari, CFO of SI-Bone, Inc. (NASDAQ:SIBN), sold 3,318 shares of company stock for $42,707 on April 2, 2026. These sales were not discretionary but were made to cover tax obligations related to the vesting of restricted stock units. Despite an overall 33% decline year-to-date, the stock has recently shown a 6.8% gain over the past week, and analysts maintain positive ratings following strong Q4 2025 financial results.
Tax-driven share sale by SI-BONE (SIBN) chief legal officer
Michael A. Pisetsky, SI-BONE's SVP and Chief Legal Officer, sold 3,134 shares of common stock on April 1-2 to cover tax withholding obligations associated with vesting restricted stock units. These "sell to cover" transactions were not discretionary trades, with sale prices ranging from $12.55 to $13.09 per share. Following these sales, Pisetsky holds 282,840 shares directly, including 151,034 shares issuable from restricted stock units.
SI-BONE Inc stock: Why this medtech innovator could reshape spine surgery
SI-BONE Inc. is highlighted as a promising medtech innovator focusing on sacroiliac (SI) joint dysfunction, a common cause of chronic lower back pain. The article suggests that SI-BONE's minimally invasive iFuse system positions it as a leader in an underserved market with high growth potential. Investors are encouraged to consider SI-BONE for its niche specialization, strong clinical data, and increasing market adoption, despite risks like reimbursement variability and competition.
SI-BONE Inc stock: Why this medtech innovator could reshape spine surgery
SI-BONE Inc. is highlighted as a medical technology innovator focusing on sacroiliac (SI) joint dysfunction, an often-overlooked cause of chronic low back pain. The company's minimally invasive iFuse system for SI joint fusion offers a unique solution in the orthopedic market, positioning it as a leader in an underserved niche. Investors are urged to consider SI-BONE for its growth potential, strong market opportunity, and robust financial health, despite typical medtech investment risks.
Si-Bone CFO Maheshwari sells $42,707 in stock
SI-Bone, Inc. CFO Anshul Maheshwari sold 3,318 shares of common stock for a total of $42,707 to cover tax withholding obligations related to restricted stock units vesting. Despite the stock being down 33% year-to-date, SI-Bone maintains a strong balance sheet with more cash than debt and a current ratio of 8.55. The company recently reported strong Q4 2025 financial results, with EPS and revenue exceeding forecasts, leading Truist Securities and Piper Sandler to reiterate positive ratings and price targets.
SI-BONE Inc Stock: Innovating Sacroiliac Joint Fusion in a Competitive Medtech Landscape
SI-BONE Inc (ISIN: US8255921098) is a medical technology company specializing in minimally invasive solutions for sacroiliac joint disorders, with its iFuse system being a market leader. This analysis explores its business model, market position, and growth opportunities within the orthopedic and spine segment, driven by demographic trends and a strong clinical evidence base. While enjoying a first-mover advantage and patent protection, the company faces risks such as reimbursement pressures and competitive innovation, making quarterly procedure growth and surgeon adoption key metrics for investors to monitor.
SI-BONE raises 2025 revenue guidance to $195M-$198M with accelerated cash flow milestones
SI-BONE has increased its 2025 revenue guidance to a range of $195 million to $198 million. This updated outlook also includes accelerated milestones for cash flow, indicating a stronger financial performance than previously anticipated.
SI-BONE raises 2025 revenue guidance to $195M-$198M with accelerated cash flow milestones
SI-BONE has increased its revenue guidance for 2025 to $195 million - $198 million, up from previous projections. This updated guidance also includes accelerated cash flow milestones, indicating an improved financial outlook and operational efficiency for the company.
SiBone (NASDAQ:SIBN) Upgraded by Wall Street Zen to Buy Rating
Wall Street Zen has upgraded SiBone (NASDAQ:SIBN) from "hold" to "buy," contributing to a consensus "Moderate Buy" rating with an average target price of $24.67. Despite beating EPS estimates and revenue expectations, SiBone remains unprofitable with a negative net margin. Insider sales of approximately $3.14 million contrast with institutional investors owning around 98.11% of the company's stock.
Vanguard files 13G/A showing 0 shares in SI-BONE (SIBN)
The Vanguard Group filed an amended Schedule 13G/A for SI-BONE (SIBN), reporting 0 shares beneficially owned, representing 0% of the class. This change is due to an internal realignment where certain Vanguard subsidiaries will now report ownership separately, as per SEC Release No. 34-39538. The filing explicitly states that this is a reporting change, not a sale or purchase of shares, and does not impact SI-BONE's outstanding share count.
Piper Sandler reiterates SI-BONE stock rating on growth outlook By Investing.com
Piper Sandler reiterated an Overweight rating and a $25.00 price target for SI-BONE Inc. (NASDAQ:SIBN), citing opportunities for more than 20% growth and an improving profitability outlook. Despite recent stock declines, Piper Sandler views SI-BONE as underappreciated, highlighting its strong gross profit margin and recent positive financial results, including an EPS beat in Q4 2025. Another firm, Truist Securities, also raised its price target for SI-BONE to $24, maintaining a Buy rating.
(SIBN) Movement as an Input in Quant Signal Sets
This article provides an AI-driven quantitative analysis for Si-bone Inc. (NASDAQ: SIBN), indicating weak near- and mid-term sentiment and a neutral long-term outlook. It details three trading strategies—Position, Momentum Breakout, and Risk Hedging—with specific entry, target, and stop-loss levels. The analysis also includes multi-timeframe signal strengths and support/resistance levels, generated by AI models for institutional trading.
SI-BONE outlines 14%-16% revenue growth for 2026 with new product launches and Smith & Nephew partnership
SI-BONE, a medical device company, projects a 14%-16% revenue growth for 2026, driven by new product introductions and its strategic partnership with Smith & Nephew. This outlook indicates the company's confidence in leveraging innovation and collaborations to expand its market presence and financial performance.
Jim Cramer on SI-BONE, Inc.: "We're not going to buy the money losers"
Jim Cramer expressed a strong negative sentiment towards SI-BONE, Inc., stating he would not recommend buying "money losers." His comment implies a lack of confidence in the company's financial performance or profitability prospects.
[Form 4] SI-BONE, Inc. Insider Trading Activity
SI-BONE, Inc. director Mika Nishimura reported an open-market sale of 4,100 shares of common stock on March 12, 2026, at a weighted average price of $13.8293 per share. Following this transaction, Nishimura directly holds 32,716 shares, including 8,675 shares issuable upon settlement of restricted stock units. This event is characterized as a routine portfolio adjustment by an insider, with no derivative transactions reported.
Nishimura Mika, Si-Bone director, sells $56k in SIBN stock
SI-BONE director Nishimura Mika recently sold 4,100 shares of SIBN common stock for approximately $56,700, with prices ranging from $13.82 to $13.86 per share. This transaction occurred on March 12, 2026, as the stock trades near its 52-week low. Despite the stock sale, SI-BONE Inc. reported strong financial results for Q4 2025, outperforming EPS and revenue forecasts, which led Truist Securities to raise its price target for the company.
Jim Cramer on SI-BONE, Inc.: “We’re Not Going to Buy the Money Losers”
Jim Cramer expressed a strong disinclination to invest in companies losing money, specifically mentioning SI-BONE, Inc. (NASDAQ: SIBN) after a caller noted its 30% decline. He emphasized focusing on profitable stocks, especially during challenging market conditions. Cramer had previously called SI-BONE a "great speculation" and mentioned researching it further in January.
[144] SI-BONE, Inc. SEC Filing
This article reports on SI-BONE, Inc.'s SEC Form 144 filing, which is a Notice of Proposed Sale of Securities pursuant to Rule 144. The filing details the proposed sale of 4,100 shares of common stock by an unnamed person to be sold through Morgan Stanley Smith Barney LLC, with an aggregate market value of $56,700.13. The shares were acquired on June 9, 2023, as restricted stock from the Issuer.
SiBone (NASDAQ:SIBN) Receives Consensus Recommendation of "Moderate Buy" from Analysts
SiBone (NASDAQ:SIBN) has received a "Moderate Buy" consensus rating from analysts, with an average 12-month target price of $24.67. Several analysts recently updated their price targets and ratings, predominantly advocating for a "buy" stance. The article also details recent insider stock sales and institutional investor activity, highlighting both share reductions and increases, and provides an overview of SiBone's financial performance and company profile.
American Century Companies Inc. Acquires 521,683 Shares of SiBone $SIBN
American Century Companies Inc. increased its stake in SiBone (NASDAQ:SIBN) by 22.5%, acquiring an additional 521,683 shares and now holding a total of 2,838,107 shares valued at $41.8 million. SiBone reported a smaller-than-expected quarterly loss of $0.04 per share, beating estimates by $0.09, and generated revenues of $56.35 million. Analysts currently have a "Moderate Buy" rating for SiBone with a consensus target price of $24.67.
SIBN Earning Date, Earning Analysis and Earning Prediction
This article provides an earnings analysis and prediction for SIBN, detailing past quarterly results, future forecasts, and stock price reactions to earnings reports. It highlights analyst estimates for 2026/Q1, which include projected revenue of $52.69M and an EPS of -$0.15, and discusses how earnings forecast revisions correlate with stock price movements. The article also touches on SIBN's recent Q4 2025 earnings call, emphasizing strong growth prospects despite minor financial misses.
SIBN Financials: Income Statement, Balance Sheet & Cash Flow
This article provides a detailed financial overview of Si-Bone (SIBN), including its income statement, balance sheet, cash flow statement, and key financial ratios through fiscal year 2025. It highlights the company's strong revenue growth, conservative leverage, and comfortable liquidity, but also points out low profitability, negative free cash flow, and low earnings quality. The analysis includes a Piotroski F-Score, an earnings quality assessment, and an interest coverage ratio to evaluate Si-Bone's overall financial health.
SI-BONE Inc reports results for the quarter ended December 31 - Earnings Summary
SI-BONE Inc has reported its earnings results for the quarter that ended on December 31. The summary of these results was published by Refinitiv and made available through TradingView. Further details on the earnings are accessible for users who log in or create an account.
Smith+Nephew signs distribution agreement with SI-BONE
Smith+Nephew has announced a distribution agreement with SI-BONE for their iFuse TORQ portfolio, which offers solutions for percutaneous pelvic fracture fixation and SI joint fusion. This partnership aims to expand Smith+Nephew's offerings in trauma procedures and leverage SI-BONE's innovative technology, including the iFuse TORQ TNT device with FDA Breakthrough Device Designation and Medicare NTAP eligibility. The collaboration is expected to enhance access to differentiated solutions and improve patient outcomes through increased surgeon engagement.
Spartan Medical Inc. and SI-BONE Inc. Proudly Announce New Partnership to Expand Access For Veterans & Wounded Warriors
Spartan Medical Inc., a Service-Disabled Veteran-Owned Small Business, has partnered with SI-BONE, Inc., a leader in sacroiliac (SI) joint solutions, to provide advanced, ultra-minimally invasive treatment options for Veterans and wounded warriors with SI joint dysfunction. This collaboration aims to address the significant gap in long-term solutions for SI joint pain within VA and DoD facilities. The partnership will make SI-BONE’s iFuse INTRA X® procedure accessible to more patients through Spartan Medical's contract-ready programs and logistics support.
SI‑BONE (SIBN) Losses Narrow In Q4 And Test Bearish Narratives On Profit Path
SI-BONE (SIBN) reported Q4 2025 revenue of US$56.4 million and a narrowed basic EPS loss of US$0.04, finishing FY 2025 with US$200.9 million in revenue and a US$0.44 TTM EPS loss. The company has shown shrinking losses over the past five years, with TTM net losses decreasing from US$37.4 million to US$18.9 million, which bulls interpret as a positive long-term trend despite analysts not expecting profitability within the next three years. Its valuation metrics include a P/S ratio of 3.3x, compared to a peer average of 4.1x and an industry average of 3.0x, alongside an analyst price target of US$25.60.
SI-BONE, Inc. (NASDAQ:SIBN) Q4 2025 Earnings Call Transcript
SI-BONE, Inc. (NASDAQ:SIBN) reported strong Q4 and full-year 2025 results, with record annual worldwide revenue of nearly $201 million and positive adjusted EBITDA for the full year. The company launched a new product, INTRA Ti, and announced a strategic partnership with Smith & Nephew to expand its trauma market reach. Management provided an outlook for 2026 expecting worldwide revenue of $228.5 million to $232.5 million, emphasizing a back-half weighted growth driven by new product launches and expanded market penetration.
SI-BONE (SIBN) 2025 10-K shows narrowing losses and $3.5B+ market
SI-BONE, Inc. (SIBN) filed its 2025 Annual Report (Form 10-K), detailing a focus on minimally invasive solutions for sacroiliac joint dysfunction, thoracolumbar fixation and fusion, and pelvic trauma with an estimated U.S. addressable market exceeding $3.5 billion. The report shows narrowing net losses to $18.9 million in 2025 from $30.9 million in 2024, despite an accumulated deficit of $450.3 million. Key highlights include new product launches, regulatory breakthroughs, and extensive clinical evidence supporting its iFuse implant family, alongside discussions of persistent competitive pressures, supply chain risks, and regulatory scrutiny.
SI-Bone (SIBN) Submits Automatic Mixed Securities Shelf Filing
SI-BONE Inc (SIBN) has submitted an automatic mixed securities shelf filing, providing it with financial flexibility for future fundraising and strategic growth. While the medical device company shows strong gross margins and liquidity, it faces challenges with profitability and has seen insider selling activity. Analysts have a positive outlook, and the stock’s valuation metrics suggest potential undervaluation.
Si-Bone Files For Mixed Shelf Size Not Disclosed
Si-Bone (SIBN) has filed for a mixed shelf offering, according to a Reuters report. The size of the offering was not disclosed. This news is relevant for investors tracking IPOs and US stocks.
SI-BONE inks 50,000-square-foot lease in San Jose
SI-BONE, a company specializing in technology for sacropelvic disorder treatment, has signed a lease for a 50,000-square-foot space in North San Jose. This new facility is more than double the size of its current 23,000-square-foot headquarters. The move signifies an expansion for the company.
SI-BONE, Inc. Reports Record Financial Results for the Fourth Quarter 2025 and Issues 2026 Guidance
SI-BONE, Inc. announced record financial results for the fourth quarter and full fiscal year 2025, with worldwide revenue growth exceeding 20% for the full year and positive adjusted EBITDA. The company reported $56.3 million in revenue for Q4 2025 and $200.9 million for the full year, along with positive adjusted EBITDA of $5.1 million in Q4 and $8.9 million for the full year. SI-BONE also provided 2026 financial guidance, projecting worldwide revenue between $228.5 million and $232.5 million, representing 14% to 16% year-over-year growth, and anticipating increased positive adjusted EBITDA.
SI-BONE Inc. (SIBN) Stock Rises on Q4 2025 Earnings
SI-BONE Inc. (SIBN) reported fourth-quarter 2025 revenue of $56.35 million, missing analyst estimates but still up 15.0% year-over-year. Despite top-line growth, the company experienced a widening net loss and diluted EPS decline, though its stock rose 3.03% post-market close. Insider trading shows significant sales by executives, while institutional investors present a mixed picture with both large additions and removals of shares.
Si-Bone: Fourth Quarter Financial Overview
Si-Bone Inc. reported a net loss of $1.6 million, or 4 cents per share, for the fourth quarter, surpassing analysts' expectations of a 13-cent loss. The medical device manufacturer achieved $56.4 million in revenue for the quarter and a total annual revenue of $200.9 million with a $18.9 million loss. The company projects future full-year revenue to be between $228.5 million and $232.5 million.
Earnings call transcript: Si-Bone Q4 2025 reports strong revenue growth and EPS beat
Si-Bone (SIBN) reported strong Q4 2025 financial results, with EPS of -$0.04 significantly beating the -$0.12 forecast and revenue reaching $56.3 million, exceeding expectations of $54.7 million. The company achieved a 15% revenue growth year-over-year, positive cash flow, and positive adjusted EBITDA for the first time, leading to a modest 0.97% increase in stock price. Looking ahead, Si-Bone projects continued revenue growth by FY2026 and plans to expand product offerings and market penetration, especially with new products like INTRA Ti and strategic partnerships.
Smith+Nephew signs distribution agreement with SI-BONE
Smith+Nephew has signed a distribution agreement with SI-BONE, focusing on SI-BONE's iFuse TORQ portfolio for percutaneous pelvic fracture fixation procedures. This partnership aims to expand Smith+Nephew’s offerings, strengthen its position in trauma procedures, and leverage SI-BONE's innovative solutions, including the iFuse TORQ TNT which has an FDA Breakthrough Device Designation. The collaboration is expected to enhance access to differentiated solutions and improve patient outcomes in pelvic fracture and SI joint fusion.
Si-Bone: Fourth Quarter Financial Overview
Si-Bone Inc. reported a net loss of $1.6 million (4 cents per share) for the fourth quarter, outperforming analysts' expectations of a 13-cent loss per share. The medical device manufacturer generated $56.4 million in revenue for the quarter and projects full-year revenue for the upcoming fiscal year to be between $228.5 million and $232.5 million. For the full fiscal year, the company had a total loss of $18.9 million on $200.9 million in revenue.
Si-Bone, Inc. Announces Executive Appointments
Si-Bone, Inc. has announced two key executive appointments. Anshul Maheshwari has been promoted to Chief Operating Officer, retaining his role as Chief Financial Officer, effective February 22, 2026. Jeff Zigler has also been promoted to Senior Vice President of Market Access and Reimbursement.
SI-BONE, Inc. Reports Record Financial Results for the Fourth Quarter 2025 and Issues 2026 Guidance
SI-BONE, Inc. announced record financial results for the fourth quarter and full fiscal year 2025, with worldwide revenue growth of 15.0% and 20.2% respectively, and positive adjusted EBITDA for both periods. The company also provided 2026 financial guidance, projecting worldwide revenue between $228.5 million and $232.5 million. These strong results were attributed to disciplined execution, a differentiated platform, and robust demand, with expectations for continued profitable growth driven by favorable reimbursement, expanding commercial reach, and new product launches.
Medicare may pay $4,136 extra per case for iFuse TORQ TNT
Smith+Nephew has entered a distribution agreement with SI-BONE to include the iFuse TORQ portfolio, enhancing its offerings for percutaneous pelvic fracture fixation and sacroiliac joint fusion. The iFuse TORQ TNT, which has FDA Breakthrough Device Designation and is NTAP-eligible, could provide up to $4,136 in additional Medicare reimbursement per procedure. This collaboration aims to broaden Smith+Nephew's trauma and extremities portfolio and deepen surgeon engagement.
SI-BONE, Inc. Reports Record Financial Results for the Fourth Quarter 2025 and Issues 2026 Guidance
SI-BONE, Inc. reported record financial results for the fourth quarter and full year 2025, with worldwide revenue growth exceeding 20% for the fiscal year and positive adjusted EBITDA. The company achieved $56.3 million in revenue for Q4 2025 and $200.9 million for the full year 2025. SI-BONE also provided 2026 guidance, projecting worldwide revenue between $228.5 million and $232.5 million, reflecting continued growth and increased positive adjusted EBITDA.
Si-Bone: Q4 Earnings Snapshot
Si-Bone Inc. (SIBN) reported a Q4 loss of $1.6 million, or 4 cents per share, surpassing analyst expectations for a 13-cent loss. The medical device maker recorded $56.4 million in revenue for the quarter. For the full year, Si-Bone reported a loss of $18.9 million on $200.9 million in revenue and projects fiscal year revenue between $228.5 million and $232.5 million.
Si-Bone: Q4 Earnings Snapshot
Si-Bone Inc. (SIBN) reported a fourth-quarter loss of $1.6 million, or 4 cents per share, surpassing Wall Street expectations, which predicted a loss of 13 cents per share. The medical device maker generated $56.4 million in revenue for the quarter and projects full-year revenue between $228.5 million and $232.5 million. For the entire year, the company had a loss of $18.9 million on $200.9 million in revenue.
SI-BONE Inc expected to post a loss of 13 cents a share - Earnings Preview
SI-BONE Inc (SIBN) is anticipated to report a loss of 13 cents per share, according to a Reuters earnings preview. This forecast provides an outlook on the company's financial performance. The article is a brief financial news item from Refinitiv.
A Look Ahead: SI-BONE's Earnings Forecast
SI-BONE (NASDAQ: SIBN) is scheduled to release its quarterly earnings report on Monday, February 23, 2026. Analysts project an EPS of $-0.13 for the company. Historically, positive earnings have led to a stock price increase, though shares are currently down 10.79% over the past year.
Insider Selling: SiBone (NASDAQ:SIBN) CEO Sells 93,475 Shares of Stock
SiBone (NASDAQ:SIBN) CEO Laura Francis sold 93,475 shares of company stock for approximately $1.43 million on February 17th, reducing her stake by 14.65%. Following the sale, shares traded up about 3.2% to $15.74. Analysts currently rate SiBone as a "Moderate Buy" with an average price target of $24.33, and institutional ownership remains very high at around 98%.
SiBone (NASDAQ:SIBN) SVP Michael Pisetsky Sells 20,756 Shares
SiBone (NASDAQ:SIBN) SVP Michael Pisetsky sold 20,756 shares of SiBone stock on February 17th, with the transaction valued at $318,604.60. Following the sale, Pisetsky now owns 285,974 shares worth approximately $4,389,700.90, marking a 6.77% reduction in his stake. SiBone's stock traded up 3.2% to $15.74, and analysts maintain a "Moderate Buy" rating with an average target price of $24.33.
SI-BONE To Present at TD Cowen 46th Annual Health Care Conference on March 2, 2026
SI-BONE, Inc. announced its participation in the TD Cowen 46th Annual Health Care Conference on March 2, 2026, where management will host a fireside chat. The event will be available via webcast for investors. SI-BONE specializes in procedural solutions for compromised bone and has a strong clinical evidence base supporting its technologies.
SI-BONE To Present at TD Cowen 46th Annual Health Care Conference on March 2, 2026
SI-BONE, Inc. (Nasdaq: SIBN), a leader in procedural solutions for compromised bone, announced its participation in the TD Cowen 46th Annual Health Care Conference. Management will host a fireside chat on March 2, 2026, at 7:30 a.m. Pacific Time/10:30 a.m. Eastern Time. The company has supported over 140,000 procedures since 2009, with its technologies backed by extensive clinical evidence.
